Guangzhou Wondfo Biotech Co., Ltd. Class A

Guangzhou Wondfo Biotech Co., Ltd. Class A

SSZSE:300482
15.28
CNY
-0.33
(-2.11%)
-0.12EPS
7.85BMarket Cap
Apr 01Next Earn

Total Valuation

CNY

As of September 30, 2026, Guangzhou Wondfo Biotech Co., Ltd. Class A carries a market capitalization of 7.85B, placing it among publicly traded companies globally. Its enterprise value stands at 6.45B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap7.85B
Enterprise Value6.45B

Important Dates

Guangzhou Wondfo Biotech Co., Ltd. Class A's next confirmed earnings release is scheduled for April 1, 2027.

Earnings Date4/1/2027

Share Statistics

As of September 30, 2026, Guangzhou Wondfo Biotech Co., Ltd. Class A has 468.15M shares outstanding.

Shares Outstanding468.15M

Valuation Ratios

These figures are as of September 30, 2026. The price-to-sales ratio is 3.98, and the price-to-book ratio stands at 1.45.

PS Ratio3.98
PB Ratio1.45
P/TBV Ratio1.56

Enterprise Valuation

These figures are as of September 30, 2026. The EV/Sales ratio of 3.28 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 6.45B versus a market cap of 7.85B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales3.28

Financial Position

As of September 30, 2026, Guangzhou Wondfo Biotech Co., Ltd. Class A maintains a current ratio of 7.34, meaning it holds 7.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 0.18, indicating conservative leverage, while an interest coverage ratio of -1.09 demonstrates limited ability to service its debt obligations.

Current Ratio7.34
Quick Ratio3.03
Debt / Equity0.18
Debt / EBITDA-0.12
Interest Coverage-1.09

Financial Efficiency

CNY

Over the twelve months ended September 30, 2026, Guangzhou Wondfo Biotech Co., Ltd. Class A posted a negative return on equity (ROE) of -1.15, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -0.97, reflecting losses generated across the asset base. The company generates approximately 804,562.78 in revenue per employee across its workforce of 2,443.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.45 indicates how many times Guangzhou Wondfo Biotech Co., Ltd. Class A sells and replaces its inventory over a year, a key working capital efficiency ratio.

Return on Equity (ROE)-1.15
Return on Assets (ROA)-0.97
Revenue Per Employee804,562.78
Employee Count2,443.00
Inventory Turnover2.45

Taxes

CNY

Over the twelve months ended September 30, 2026, Guangzhou Wondfo Biotech Co., Ltd. Class A recorded an income tax benefit of -32.96M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -90.88M and -62.89M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

Income Tax-32.96M

Stock Price Statistics

CNY

As of the close on November 17, 2026, Guangzhou Wondfo Biotech Co., Ltd. Class A's stock has declined approximately 29.68% over the past 52 weeks. The 50-day moving average sits at 16.16, while the 200-day moving average is 17.95.

52-Week Price Change-29.68%
50-Day Moving Average16.16
200-Day Moving Average17.95

Income Statement

CNY

Over the twelve months ended September 30, 2026, Guangzhou Wondfo Biotech Co., Ltd. Class A generated 1.97B in revenue and converted that into -62.89M in net income, yielding earnings per share of -0.12. EBITDA reached -81.09M, while operating income came in at 2.15M.

Revenue1.97B
Gross Profit1.15B
Operating Income2.15M
Pretax Income-90.88M
Net Income-62.89M
EBITDA-81.09M
EBIT-81.09M
Earnings Per Share (EPS)-0.12

Balance Sheet

CNY

As of September 30, 2026, Guangzhou Wondfo Biotech Co., Ltd. Class A holds 1.47B in cash and equivalents against 9.90M in total debt, resulting in a net debt position of -262.77M. Total book value stands at 5.40B, with working capital of 3.08B providing operational flexibility.

Cash & Cash Equivalents1.47B
Total Debt9.90M
Net Debt-262.77M
Equity (Book Value)5.40B
Book Value Per Share11.54
Working Capital3.08B

Cash Flow

CNY

These figures cover the twelve months ended September 30, 2026.

Capital Expenditures-205.19M

Margins

Over the twelve months ended September 30, 2026, Guangzhou Wondfo Biotech Co., Ltd. Class A posted a gross margin of 58.42, reflecting its pricing power and cost economics. The operating margin of 0.11 and net profit margin of -3.20 provide insight into operational efficiency.

Gross Margin58.42
Operating Margin0.11
Pretax Margin-4.62
Profit Margin-3.20
EBITDA Margin-4.13

Dividends & Yields

CNY

Over the twelve months ended September 30, 2026, Guangzhou Wondfo Biotech Co., Ltd. Class A paid dividends of 0.12 per share. The dividend payout ratio of -101.82 is negative because earnings are negative, so the dividend is being paid out of something other than profits, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield reaches 10.33, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Guangzhou Wondfo Biotech Co., Ltd. Class A shareholders.

Dividend Per Share0.12
Payout Ratio-101.82
Shareholder Yield10.33

Stock Splits

Guangzhou Wondfo Biotech Co., Ltd. Class A's most recent stock split took place on May 26, 2021 with a 10:13 split ratio.

Last Split Date5/26/2021
Split Ratio10:13

Scores

As of September 30, 2026, Guangzhou Wondfo Biotech Co., Ltd. Class A has an Altman Z-Score of 10.07, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score10.07